Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gd-GQD refers to *gadolinium-doped graphene quantum dots*, engineered nanomaterials in which gadolinium (Gd), a paramagnetic metal, is incorporated into graphene quantum dots (GQDs)[3][4]. These structures are designed primarily as advanced magnetic resonance imaging (MRI) contrast agents, capitalizing on the paramagnetic properties of gadolinium and the small size, water dispersibility, and traceability of GQDs[3][4]. Gd-GQDs demonstrate **significantly enhanced longitudinal relaxivity** compared to commercial Gd-based MRI agents (e.g., Gd-DTPA), providing improved image contrast at lower concentrations[3][4]. The GQD scaffold also enables additional functionalities for targeted delivery, dual-modal (fluorescence plus MRI) imaging, and possible nanotheranostic applications (e.g., in cancer therapy)[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gd-GQD.